It belongs to a class called GLP-1 receptor agonists, which mimic a natural hormone that regulates insulin and appetite
GIP works alongside GLP-1 to regulate insulin response and may also affect fat storage
These results were attributed not just to improved glycemic control, but to anti-inflammatory effects on arterial walls, reduced plaque formation, and enhanced endothelial function
In clinical trials, tirzepatide produced greater average weight loss than semaglutide, with some patients losing up to 20 to 25 percent of their body weight compared to 15 to 17 percent with semaglutide
Maack C, Lehrke M, Backs J, Heinzel FR, Hulot JS, Marx N, Paulus WJ, Rossignol P, Taegtmeyer H, Bauersachs J, et al
Insurance coverage for tirzepatide varies, but many major insurers now consider this medication for weight management with a prior authorization